SOILGUARD: Advancing Towards Sustainable Soil Biodiversity Management
15 May 24
On April 19th, a full-day event was held at La Junquera regenerative farm and village. During the event, the first
On April 19th, a full-day event was held at La Junquera regenerative farm and village. During the event, the first
The consortium of the European SAbyNA project, consisting of 17 partners, gathered for the last time in person in Seville
Great news for sustainable energy! On April 18th, the M30 meeting of the GAIA project was held at FACSA’s facilities
Los miembros del proyecto X-Seed visitando el laboratorio de energía de Leitat en la sede central de Terrassa, durante el
Wageningen, The Netherlands – March 3, 2024 – In an ambitious stride towards promoting circular economy principles, the ReLEAF Consortium
On May 28th, Leitat proudly launched the SOLSTICE project, an ambitious initiative aimed at promoting sustainable growth in the textile
Leitat recently hosted the second consortium meeting of the IN-ARMOR Project in the vibrant city of Barcelona. This gathering was
El consorcio del proyecto UpSurge, formado por 23 socios, celebró su reunión de seguimiento de los 30 meses los días
El trasplante hepático es una opción terapéutica escogida para pacientes con enfermedades hepáticas terminales, pero la escasez de órganos adecuados
The recent 18-month project meeting of the NetFuels initiative concluded after two days of inspiring and productive scientific discussions in
On April 15th and 16th, representatives from Leitat, Pablo Sánchez Cueto and Dr. Aroa Rey Campa, joined the general assembly
The ZABAT Project team recently had a productive face-to-face meeting at the Fraunhofer IFAM offices in Bremen, Germany. This was
Leitat y el consorcio CashKeeper se unen en persona para iniciar un nuevo proyecto. CashKeeper, es una iniciativa conjunta que
El consorcio del proyecto REDWine, coordinado por Leitat y formado por 12 socios, se reunió los días 12 y 13
El consorcio del proyecto ZeroF, formado por 12 socios, se reunió los días 19 y 20 de marzo de 2024
• Amira therapeutics ha recibido la designación de medicamento huérfano (ODD) para su compuesto AMI463 por parte de la FDA.
Sede Central Leitat
C/ de la Innovació, 2
08225 Terrassa, (Barcelona)
Tel. (+34) 937 882 300
